Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 7/20 | 0.40 |
| ▸ | PPARA | Q07869 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11856125 | 0.85 | PPARA (0.47) | SLC6A2SLC6A3CYP2C9CYP2C19PPARG | |
| SCHEMBL4037477 | 0.84 | EPHX1 (0.44) | EPHX1CYP2C19MEN1KMT2A | |
| SCHEMBL11855776 | 0.80 | ESR1 (0.50) | SLC6A2SLC6A3PPARGPPARAMEN1 | |
| SCHEMBL6077436 | 0.73 | SLC6A4 (0.54) | EPHX1SLC6A2SLC6A3SLC6A4CYP2C9 | |
| SCHEMBL1901447 | 0.72 | SLC6A4 (0.52) | EPHX1SLC6A2SLC6A3SLC6A4CYP2C9 | |
| SCHEMBL5096121 | 0.72 | SLC6A4 (0.57) | SLC6A2SLC6A3SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL8122168 | 0.72 | SLC6A4 (0.57) | SLC6A2SLC6A3SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL6317469 | 0.72 | SLC6A4 (0.57) | SLC6A2SLC6A3SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL11850208 | 0.71 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4PPARGPPARA | |
| SCHEMBL2405210 | 0.71 | P2RX7 (0.38) | CYP2C9CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | EPHX1 2814/4885SLC6A2 589/4885SLC6A3 303/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | EPHX1 2814/4885SLC6A2 589/4885SLC6A3 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.